Weight loss drug gets US nod to treat sleep apnea

Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.
Weight Loss Drug Zepbound Could Treat Sleep Apnea Without a CPAP or Surgery
GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. Now, new research suggests Eli Lilly's weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality.
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.
Zepbound Gets FDA Approval to Treat Sleep Apnea
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA announced today.
GLP-1 Zepbound is approved as first drug for sleep apnea
The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
FDA approves weight-loss drug Zepbound to treat sleep apnea
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.
FDA approves Zepbound as a treatment for obstructive sleep apnea
Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and Drug Administration has appro
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Milwaukee Journal Sentinel4d
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication ...